Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia

Cancer Research

Volumn 73, Issue 8, 2013, Pages 2540-2550

  Bunda, Severa ^a   Kang, Michelle W ^c   Sybingco, Stephanie S ^a   Weng, Julie ^c   Favre, Helene ^c   Shin, Danielle H ^c   Irwin, Meredith S ^b   Loh, Mignon L ^b,d   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Department of Pediatrics ^*  (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; DASATINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN KINASE LYN; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE;

ARTICLE; BONE MARROW; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JUVENILE MYELOMONOCYTIC LEUKEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; DRUG RESISTANCE, NEOPLASM; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEK293 CELLS; HUMANS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-CBL; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES; UBIQUITINATION;

EID: 84876931998     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3425     Document Type: Article

References (36)

1. Loh ML. Childhood myelodysplastic syndrome: Focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. Hematol Am Soc Hematol Educ Program 2010;2010:357-62.
2. Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009;114:1859-63.
3. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010; 42:794-800.
4. Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 2010; 87:250-57.
5. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008;68:10349-57.
6. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009;113:6182-92.
7. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, et al. Gainof-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460:904-8.
8. Zhou ZR, Gao HC, Zhou CJ, Chang YG, Hong J, Song AX, et al. Differential ubiquitin binding of the UBA domains from human c-Cbl and Cbl-b: NMR structural and biochemical insights. Protein Sci 2008;17:1805-14.
9. Fukazawa T, Miyake S, Band V, Band H. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem 1996;271:14554-9.
10. Miyake S, Lupher ML Jr, Druker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc Natl Acad Sci U S A 1998;95:7927-32.
11. Wisniewski D, Strife A, Clarkson B. c-Kit ligand stimulates tyrosine phosphorylation of the c-Cbl protein in human hematopoietic cells. Leukemia 1996;10:1436-42.
12. Lupher ML Jr, Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, et al. Cbl-mediated negative regulation of the Syk tyrosine kinase: A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J Biol Chem 1998;273:35273-81.
13. Kales SC, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: The Cbl oncogene comes of age. Cancer Res 2010;70: 4789-94.
14. Zheng N, Wang P, Jeffrey PD, Pavletich NP. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 2000;102:533-9.
15. Hunter S, Burton EA, Wu SC, Anderson SM. Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase. J Biol Chem 1999;274:2097-106.
16. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-7.
17. Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 1994;84:3435-9.
18. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004;103:2325-31.
19. Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, et al. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003; 102:1474-9.
20. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008;14:335-43.
21. Bagley CJ, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activation: Lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood 1997;89: 1471-82.
22. Perugini M, Brown AL, Salerno DG, Booker GW, Stojkoski C, Hercus TR, et al. Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. Blood 2010;115:3346-53.
23. McCubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000;14:9-21.
24. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, et al. Establishment and characterization of a unique human cell line that proliferates dependently onGM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989;140:323-34.
25. Hunter T. A tail of two src's: Mutatis mutandis. Cell 1987;49:1-4.
26. Yokouchi M, Kondo T, Sanjay A, Houghton A, Yoshimura A, Komiya S, et al. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Biol Chem 2001;276:35185-93.
27. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: Accentuating the positive and the negative. Immunity 2005;22:9-18.
28. Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the children's oncology group phase I consortium. J Clin Oncol 2011;29:839-44.
29. Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-40.
30. Buitrago L, Langdon WY, Sanjay A, Kunapuli SP. Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling. Blood 2011;118:5631-40.
31. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol 2009;27:29-60.
32. Anderson SM, Burton EA, Koch BL. Phosphorylation of Cbl following stimulation with interleukin-3 and its association with Grb2, Fyn, and phosphatidylinositol 3-kinase. J Biol Chem 1997;272: 739-45.
33. Williams NG, Roberts TM, Li P. Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. Proc Natl Acad Sci U S A 1992;89:2922-6.
34. Chan PC, Chen HC. p120RasGAP-mediated activation of c-Src is critical for oncogenic Ras to induce tumor invasion. Cancer Res 2012;72:2405-15.
35. Shields DJ, Murphy EA, Desgrosellier JS, Mielgo A, Lau SK, Barnes LA, et al. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 2011;30:2123-34.
36. Ma YC, Huang J, Ali S, Lowry W, Huang XY. Src tyrosine kinase is a novel direct effector of G proteins. Cell 2000;102: 635-46.